450 DavOr Capitol employees received their first dose of Sinovac

Date:

Share post:

The one-day vaccination program has prioritized Capitol workers who has comorbidities that puts them in the A3 category of the Department of Health’s (DOH’s) COVID-19 Vaccination Program’s prioritization framework.

Vaccination was conducted following the inoculation of individuals who falls on the A1 and A2 categories that specifically refers to the frontline health services workers and senior citizens.

To ensure smooth and organized flow of the rollout, organizers has implemented several steps or processes in order to prevent the event from becoming a super spreader that has been blamed as among those that caused the sudden spike of Covid cases. Before the workers got the much-needed jabs, they earlier went through a registration process, then counselling and the checking of body vital signs. 

It was followed by a meticulous screening of individuals that categorized them through a color coding scheme: Green, Yellow and Orange. Green signifies that the individual has no sickness or is deemed normal, on the other hand, yellow means that an individual has a comorbidity, and orange is an indication that an individual has two or more comorbidities.-PIO (DavOr)

RIZAL MEMORIAL COLLEGEspot_img

Related articles

Filipino Coffee Eyes Global Market as Farmers Chase Premium Prices

TACURONG CITY (May 29) — The Philippine coffee industry is pushing deeper into the global specialty market, with...

Davao Oriental Unveils Tourism Brand Anchored on Hamiguitan, Local Pride

MATI CITY (May 29) — Davao Oriental has launched a new tourism identity centered on pride of place,...

DAR Land Titling Push Tests Indigenous Rights in Surigao Norte

SURIGAO CITY (May 29) — The government’s aggressive push to accelerate land titling under President Ferdinand Marcos Jr.’s...

ICC Races to Lock Duterte Trial as Court Tightens Deadlines, Evidence Rules

MANILA (May 29) — The International Criminal Court is moving with increasing urgency to lock down the trial...